Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Viking Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company, is advancing a dual GLP-1/GIP agonist, VK2735, for treating obesity for both subcutaneous and oral administration
Source: FDA Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDAs Ongoing Evaluation of Reports of Suicidal Thoughts or Actions ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs
Insulin is the oldest and most powerful glucose-lowering tool in the room
Immunogenicity of exenatide may lead to the formation of anti-drug antibodies, reducing the medications efficacy and causing injection-site reactions (49)
Gut related adverse effects manifested in more than half of the people receiving Lixisenatide
Despite the lack of efficacy, Chin emphasized the trial was impressive and well conducted
